Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice-Reference-Cited by-同舟云学术

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

Published:2021-09-29 Issue: Volume: Page:
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Hayakawa Yuka,Tsuchiya Kaoru,Kurosaki Masayuki,Yasui Yutaka,Kaneko Shun,Tanaka Yuki,Ishido Shun,Inada Kento,Kirino Sakura,Yamashita Koji,Nobusawa Tsubasa,Matsumoto Hiroaki,Kakegawa Tatsuya,Higuchi Mayu,Takaura Kenta,Tanaka Shohei,Maeyashiki Chiaki,Tamaki Nobuharu,Nakanishi Hiroyuki,Itakura Jun,Takahashi Yuka,Asahina Yasuhiro,Okamoto Ryuichi,Izumi Namiki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01185-4.pdf

Reference32 articles.

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

2. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

3. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

4. Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66

5. Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?;World Journal of Gastrointestinal Pharmacology and Therapeutics;2024-09-05

2. The current status and future of targeted-immune combination for hepatocellular carcinoma;Frontiers in Immunology;2024-08-05

3. Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies;JHEP Reports;2024-08

4. A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma;J TRANSL INTERN MED;2024

5. Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice;Oncology Letters;2024-06-25